5-Fluorouracil-induced coronary vasospasm.

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• 5-fluorouracil (5-FU) is a widely used chemotherapy agent.
• Cardiotoxicity from 5-FU is a rare but severe adverse event, affecting less than 1% of patients.
• Cardiotoxic events associated with 5-FU can include myocardial infarction, angina, and arrhythmias.

Observation:

• A case study detailing coronary vasospasm induced by parenteral 5-FU administration.
• The patient experienced cardiac symptoms directly linked to 5-FU treatment.
• Symptoms resolved and did not reappear upon switching to an oral formulation.

Findings:

• Parenteral 5-fluorouracil can precipitate coronary vasospasm.
• Oral capecitabine, a prodrug of 5-FU, did not elicit a recurrence of coronary vasospasm in this patient.
• This suggests differential toxicity profiles between parenteral 5-FU and oral capecitabine.

Implications:

• Highlights the importance of monitoring for cardiac adverse events during 5-FU therapy.
• Suggests capecitabine as a potentially safer alternative for patients experiencing 5-FU-induced cardiotoxicity, specifically coronary vasospasm.
• Underscores the need for further research into the mechanisms and management of 5-FU-related cardiotoxicity.